ACADIA Pharmaceuticals Inc (FRA:DR6)
€ 13.295 -0.225 (-1.66%) Market Cap: 2.29 Bil Enterprise Value: 1.88 Bil PE Ratio: 83.33 PB Ratio: 4.82 GF Score: 73/100

Q2 2022 ACADIA Pharmaceuticals Inc Earnings Call Transcript

Aug 08, 2022 / 08:30PM GMT
Release Date Price: €16.06 (+7.99%)
Operator

Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Second Quarter 2022 Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker, Mr. Mark Johnson, Vice President of Investor Relations at ACADIA. Please go ahead, sir.

Mark C. Johnson
ACADIA Pharmaceuticals Inc. - VP of IR

Thank you. Good afternoon, and thank you for joining us on today's call to discuss ACADIA's Second Quarter 2022 Financial Results. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer; who will provide an overview of our second quarter performance and a review of our business; Mark Schneyer, our Chief Financial Officer, will discuss our financial results and guidance; Brendan Teehan, our Chief Operating Officer, Head of Commercial, will provide updates on our commercial performance; and Kathie Bishop, our Chief Scientific Officer and Head of Rare Disease, will provide an overview on trofinetide. Dr. Serge

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot